Mounjaro in Dubai
Tirzepatide availability, pricing, brand comparison with Ozempic, research-grade access, and why researchers are moving to triple-agonist compounds in the UAE.
Mounjaro is Eli Lilly’s branded tirzepatide, a dual GLP-1/GIP receptor agonist that achieved 22.5% mean body weight reduction in SURMOUNT trials—significantly outperforming Ozempic’s 15%. In Dubai, Mounjaro has limited pharmacy availability with clinic pricing at AED 2,000–5,000+ per month. Research-grade tirzepatide is available for laboratory use, though the research frontier has moved to retatrutide (24.2% weight loss), a triple-agonist that adds the glucagon receptor for superior metabolic effects.
Retatrutide pen 30mg (3 receptors vs Mounjaro’s 2, 24.2% weight loss data). 99.262% HPLC purity. 2-hour Dubai delivery.
What Is Mounjaro?
Mounjaro is the brand name for tirzepatide, a dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor agonist manufactured by Eli Lilly. It was approved for type 2 diabetes management and is the first dual-incretin agonist to reach market. The same tirzepatide molecule is also marketed as Zepbound, approved specifically for chronic weight management.
Mounjaro’s “twincretin” mechanism activates two incretin receptors simultaneously, producing superior metabolic effects compared to single-agonist GLP-1 compounds like semaglutide. In the SURMOUNT-1 trial, tirzepatide at the highest dose achieved 22.5% mean body weight reduction—a 50% improvement over semaglutide’s 15%. For detailed tirzepatide pharmacology and dosing, see our tirzepatide in Dubai guide.
Mounjaro Availability & Pricing in Dubai
Pharmacy Stock
Mounjaro availability in Dubai is limited and inconsistent. While approved in the UAE, pharmacy distribution has not kept pace with demand. Clinic wait times of 2–8 weeks are common, and not all dose strengths may be available simultaneously. Zepbound (the weight-management indication) has even more limited distribution in the region.
Clinic Pricing
Dubai clinics prescribing Mounjaro for weight management charge AED 2,000–5,000+ per month, including consultation, monitoring, and the medication itself. Prices vary significantly between clinics. Insurance coverage for weight-management prescriptions is inconsistent across UAE providers, with many plans excluding obesity treatments.
Research-Grade Access
Research-grade tirzepatide (the same molecule as Mounjaro) is available in Dubai for in-vitro laboratory use without pharmacy constraints. Remy Peptides provides HPLC-verified tirzepatide with published COA documentation and consistent supply. Contact us via WhatsApp for current pricing and formats.
Mounjaro vs Ozempic
The two leading branded weight-loss injectables differ fundamentally in mechanism and efficacy:
| Feature | Mounjaro | Ozempic |
|---|---|---|
| Molecule | Tirzepatide | Semaglutide |
| Receptors | GLP-1 + GIP (2) | GLP-1 only (1) |
| Weight Loss | 22.5% (SURMOUNT-1) | ~15% (STEP 1) |
| Manufacturer | Eli Lilly | Novo Nordisk |
| Dubai Price | AED 2,000–5,000+/mo | AED 1,500–4,000+/mo |
| Availability | Limited | Intermittent (shortage) |
Mounjaro’s dual-receptor mechanism provides a 50% greater weight loss effect compared to Ozempic. The GIP receptor component enhances insulin sensitivity and may improve lipid metabolism beyond what GLP-1 alone achieves. For a detailed side-effect comparison, see our Mounjaro/tirzepatide injection guide.
Research-Grade Tirzepatide Access
Research-grade tirzepatide provides the same molecule as Mounjaro for in-vitro laboratory use, with several advantages for researchers:
- No shortage constraints: Supply is independent of pharmaceutical distribution channels
- HPLC purity verification: Published COA documentation that branded products do not provide
- Competitive pricing: Significantly lower cost than clinic-prescribed Mounjaro
- Consistent availability: No waitlists or prescription requirements for laboratory research
For detailed tirzepatide pharmacology, SURMOUNT trial data, and titration protocols, see our comprehensive tirzepatide in Dubai guide.
Why Researchers Are Moving to Triple Agonists
While Mounjaro advanced the field from single to dual agonism, the research frontier has moved to triple-receptor compounds. Retatrutide adds the glucagon receptor to GLP-1 and GIP, producing three distinct metabolic effects:
- GLP-1: Appetite suppression and delayed gastric emptying (shared with Mounjaro)
- GIP: Enhanced insulin sensitivity and lipid metabolism (shared with Mounjaro)
- Glucagon: Increased energy expenditure and hepatic lipid oxidation (unique to retatrutide)
In Phase 2 trials, retatrutide achieved 24.2% mean body weight reduction—surpassing Mounjaro’s 22.5%. The glucagon receptor component drives thermogenesis and fat oxidation that dual agonists cannot produce. Phase 3 TRIUMPH trials are underway. Remy Peptides carries research-grade retatrutide as a pre-filled pen (30mg) with 99.262% HPLC purity. See our best obesity drug 2026 analysis for the full pipeline comparison.
Delivery Across the UAE
- Dubai: 2-hour delivery — all areas
- Abu Dhabi: Next-day delivery
- Sharjah & other emirates: Next-day delivery
All shipments use temperature-controlled packaging. Contact us via WhatsApp at +34 672 737 521 for ordering and availability.
Our Research Standards
This article cites peer-reviewed studies, FDA filings, and published clinical trial data. Read our editorial policy →
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Eli Lilly and Company. Mounjaro (tirzepatide) Prescribing Information. Revised 2024.
- Jastreboff AM, et al. Retatrutide Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
Retatrutide Pen 30 mg
Next-generation triple agonist. 24.2% weight loss data. 99.262% HPLC purity. 2-hour Dubai delivery.
Order Retatrutide Pen →